NON-TOXIC BIOFILM INHIBITOR
    6.
    发明申请
    NON-TOXIC BIOFILM INHIBITOR 有权
    非毒性生物膜抑制剂

    公开(公告)号:US20120016102A1

    公开(公告)日:2012-01-19

    申请号:US13179058

    申请日:2011-07-08

    IPC分类号: C07K7/08 C07K14/00

    摘要: The present invention relates to a composition, device and method for preventing or inhibiting biofilm formation on biotic or abiotic surfaces. The composition comprises a peptide based on the C-terminal receptor binding domain of Pseudomonas aeruginosa type IV pilin, which binds to an abiotic surface (e.g., steel, plastic) with high affinity and prevents binding of a variety of P. aeruginosa strains to the surface. The inventive composition represents a non-toxic inhibitor for biofilm formation, particularly on an abiotic surface, which is responsible for a large number of problematic diseases and massive economic losses. The inventive method is useful as a safe and environmentally friendly means of modifying a surface of a variety of biomedical, nanotechnological, and biotechnological devices or articles.

    摘要翻译: 本发明涉及在生物或非生物表面上预防或抑制生物膜形成的组合物,装置和方法。 组合物包含基于铜绿假单胞菌IV型皮林的C-末端受体结合结构域的肽,其以高亲和力结合非生物表面(例如,钢,塑料),并防止多种铜绿假单胞菌菌株与 表面。 本发明的组合物代表用于生物膜形成的无毒性抑制剂,特别是在非生物表面上,其负责大量有问题的疾病和巨大的经济损失。 本发明的方法可用作改变各种生物医学,纳米技术和生物技术装置或制品的表面的安全和环境友好的手段。

    Non-Toxic Biofilm Inhibitor
    7.
    发明申请
    Non-Toxic Biofilm Inhibitor 有权
    无毒生物膜抑制剂

    公开(公告)号:US20080287367A1

    公开(公告)日:2008-11-20

    申请号:US11996379

    申请日:2006-07-21

    IPC分类号: A01N37/18 C07K7/00 A01P1/00

    摘要: The present invention relates to a composition and method for preventing or inhibiting biofilm formation on biotic or abiotic surfaces. The composition comprises a peptide based on the C-terminal receptor binding domain of Pseudomonas aeruginosa type IV pilin, which binds to an abiotic surface (e.g., steel, plastic) with high affinity and prevents binding of a variety of P. aeruginosa strains to the surface. The inventive composition represents a non-toxic inhibitor for biofilm formation, particularly on an abiotic surface, which is responsible for a large number of problematic diseases and massive economic losses. The inventive method is useful as a safe and environmentally friendly means of modifying a surface of a variety of biomedical, nanotechnological, and biotechnological devices or articles.

    摘要翻译: 本发明涉及在生物或非生物表面上预防或抑制生物膜形成的组合物和方法。 组合物包含基于铜绿假单胞菌IV型皮林的C-末端受体结合结构域的肽,其以高亲和力结合非生物表面(例如,钢,塑料),并防止多种铜绿假单胞菌菌株与 表面。 本发明的组合物代表用于生物膜形成的无毒性抑制剂,特别是在非生物表面上,其负责大量有问题的疾病和巨大的经济损失。 本发明的方法可用作改变各种生物医学,纳米技术和生物技术装置或制品的表面的安全和环境友好的手段。

    Method of prevention of pseudomonas infection
    8.
    发明授权
    Method of prevention of pseudomonas infection 失效
    预防假单胞菌感染的方法

    公开(公告)号:US5468484A

    公开(公告)日:1995-11-21

    申请号:US84739

    申请日:1993-06-28

    摘要: The invention described includes methods and compositions useful in preventing infection by Pseudomonas aeruginosa and related organisms. Diclosed is a peptide having the sequence corresponding to an antigenic site in the protein exoenzyme S which is antigenically similar to a C-terminal portion of the Pseudomonas aeruginosa pilin protein. The peptide is cross-reactive with surface peptides present in certain bacterial and fungal microorganisms, and is effective in inhibiting binding of such organisms to target epithelial cells. The peptide may also be employed in a vaccine composition, for producing immunity against Pseudomonas aeruginosa as well as against such cross-reactive microorganisms.

    摘要翻译: 所描述的发明包括可用于预防铜绿假单胞菌和相关生物体感染的方法和组合物。 被分离的是具有与蛋白质外切酶S中的抗原位点相对应的序列的肽,其与铜绿假单胞菌皮林蛋白质的C末端部分具有抗原性。 该肽与某些细菌和真菌微生物中存在的表面肽具有交叉反应性,并且有效抑制这些生物体与目标上皮细胞的结合。 肽也可以用于疫苗组合物中,用于产生针对铜绿假单胞菌的免疫以及针对这种交叉反应性微生物。

    Non-toxic biofilm inhibitor
    9.
    发明授权
    Non-toxic biofilm inhibitor 有权
    无毒生物膜抑制剂

    公开(公告)号:US07976851B2

    公开(公告)日:2011-07-12

    申请号:US11996379

    申请日:2006-07-21

    摘要: The present invention relates to a composition and method for preventing or inhibiting biofilm formation on biotic or abiotic surfaces. The composition comprises a peptide based on the C-terminal receptor binding domain of Pseudomonas aeruginosa type IV pilin, which binds to an abiotic surface (e.g., steel, plastic) with high affinity and prevents binding of a variety of P. aeruginosa strains to the surface. The inventive composition represents a non-toxic inhibitor for biofilm formation, particularly on an abiotic surface, which is responsible for a large number of problematic diseases and massive economic losses. The inventive method is useful as a safe and environmentally friendly means of modifying a surface of a variety of biomedical, nanotechnological, and biotechnological devices or articles.

    摘要翻译: 本发明涉及在生物或非生物表面上预防或抑制生物膜形成的组合物和方法。 组合物包含基于铜绿假单胞菌IV型皮林的C-末端受体结合结构域的肽,其以高亲和力结合非生物表面(例如,钢,塑料),并防止多种铜绿假单胞菌菌株与 表面。 本发明的组合物代表用于生物膜形成的无毒性抑制剂,特别是在非生物表面上,其负责大量有问题的疾病和巨大的经济损失。 本发明的方法可用作改变各种生物医学,纳米技术和生物技术装置或制品的表面的安全和环境友好的手段。

    Vaccine for Pseudomonas aeruginosa
    10.
    发明授权
    Vaccine for Pseudomonas aeruginosa 失效
    绿脓杆菌疫苗

    公开(公告)号:US06541007B1

    公开(公告)日:2003-04-01

    申请号:US09345624

    申请日:1999-06-30

    IPC分类号: A61K39385

    摘要: A C-terminal pilin peptide vaccine for immunizing or treating a patient for infection by a Pseudomonas aeruginosa (PA) infection is disclosed. The peptide comprises the peptide identified as SEQ ID NOS. 3-6; and a carrier protein conjugated to the peptide. Also disclosed is a pilin peptide C-terminal PA pilin peptide having the amino acid sequence identified as SEQ ID NO:3, and analogs thereof having one of residues T, K, or A at position 130, D, T, or N at position 132, Q, A, or V at position 133, E, P, N, or A at position 135, Q, M, or K at position 136, and I, T, L, or R at position 138, excluding SEQ ID NOS: 1, 2, 9, 10, and 11, and the ability to cross-react with antibodies against the corresponding C-terminal peptides from PA strains PAK and PAO.

    摘要翻译: 公开了用于免疫或治疗患者感染铜绿假单胞菌(PA)感染的C末端蛋白肽疫苗。 肽包含鉴定为SEQ ID NOS的肽。 3-6; 和与肽结合的载体蛋白。 还公开了具有鉴定为SEQ ID NO:3的氨基酸序列的pilin肽C-末端肽肽素,其类似物在位置130,D,T或N位置上具有残基T,K或A之一的位置 132位的Q,A或V位于第136位的第135位,第13位,第13位,第13位,第13位,第13位,第13位,第13位,第13位,第13位,第13位, NOS:1,2,9,10和11,以及与来自PA菌株PAK和PAO的相应C末端肽的抗体交叉反应的能力。